In June 2024, the biopharma industry witnessed a high-stakes dance of negotiation, as Regulus Therapeutics successfully played the field to license its promising Phase Ib trial drug, farabursen, an innovative therapy for autosomal dominant polycystic kidney disease (ADPKD). The strategic maneuvers and back-and-forth exchanges underscored the fierce nature of biopharma deal-making, providing a window into […]
Tag: biotech
Exploring Anima Biotech Market Trends and Insights
The bioconvergence market has experienced rapid growth, with predictions of reaching $159.66 billion in 2025 and $243.53 billion in 2029. This growth is fueled by personalized medicine, biomedical engineering advancements, and increased healthcare digitization. Innovative trends like AI in drug discovery and lab-on-a-chip technologies are shaping the industry. Major drivers include the emphasis on personalized […]
Lilly Invests $1 Billion in Boston Gene-Editing Biotech
In a significant move, Lilly has allocated $1 billion towards a Boston-based biotech company focusing on developing a gene-editing cholesterol drug. Gene editing involves the modification of an organism’s DNA to achieve a desired trait, and in this case, it is being utilized to target cholesterol levels in the body. This substantial investment highlights the […]
Mesa Biotech Firm’s 600% Revenue Growth in 18 Months
The Mesa biotech company experienced an exceptional 600% revenue growth over just 18 months, showcasing its rapid expansion and market success. This significant increase in revenue underscores the company’s strong performance and strategic initiatives in the biotech sector. The growth rate far exceeds industry norms, positioning the company as a standout player in the American […]
Role of Remnant Cholesterol in ASCVD
Remnant cholesterol, found in triglyceride-rich lipoproteins, is a key factor in atherosclerotic cardiovascular disease (ASCVD). Dr. Børge G. Nordestgaard discussed its role as an independent risk factor for ASCVD and emerging therapies targeting residual cardiovascular risk beyond LDL cholesterol reduction. With a focus on the evolving understanding of remnant cholesterol and triglyceride-rich lipoproteins (TRLs), Dr. […]
Moderna Secures FDA Approval for Next-Gen COVID-19 Vaccine
Moderna has achieved FDA approval for its advanced COVID-19 vaccine, paving the way for commercialization in the upcoming respiratory virus season of 2025–2026. This milestone follows the FDA’s recent introduction of a revised approval framework for COVID-19 vaccines. Additionally, the announcement coincides with HHS Secretary Robert F. Kennedy Jr.’s statement regarding the exclusion of routine […]
Biotech Challenges: Accessing Innovative Healthcare
Pompe disease, a genetic disorder, is commonly treated with enzyme-replacement therapy (ERT) requiring costly weekly infusions. Despite ERT’s groundbreaking nature, many patients face barriers accessing this crucial treatment. Factors like insurance coverage, state regulations, and pre-existing conditions impact access, particularly for those without insurance or in underserved regions. Without equitable access, the potential benefits of […]
European Biotech Trends for 2025 and Beyond
In 2016, the International Consortium for Personalised Medicine (ICPerMed) was established by over 30 European members in collaboration with the European Commission. IHU PRISM, the first national center for precision medicine in oncology in France, emerged from a partnership between ICPerMed and Institut Hospitalo-Universitaire. This initiative, focusing on cancer care, received a significant €30 million […]
London Biotech Hub: Innovation in the Golden Triangle
London’s biotech hub continues to thrive as German multinational BioNTech announces plans to invest £1 billion in the U.K. for research and development of innovative medicines. This investment includes the creation of new R&D and AI hubs, positioning London as a key location for BioNTech’s expansion in the U.K. Backed by £129 million in grant […]
Zydus Strengthens Biologics Presence Through Agenus Deal
Zydus has solidified its position in the global biologics market through the acquisition of Agenus, which includes biologics manufacturing sites in Emeryville and Berkeley, California. The deal involves an upfront payment of $75 million, with an additional $50 million in milestone-based payments over three years. These facilities will support Zydus’ new biologics CDMO business, catering […]
Biotech IPO Slump Continues Amid Disappointing Returns
The biotech industry faces a prolonged IPO slump in 2026 as returns fail to meet expectations. With increasing investments in the sector and advancements in science, big pharma companies are likely to seek out firms with strong clinical data to offset revenue losses from expiring drug patents. Additionally, rising contract research costs are driving the […]
Defence Therapeutics Establishes US Laboratory in Biotech Hub
1 Defence Therapeutics has announced the opening of a new laboratory in the Boston-Cambridge biotech hub, marking a significant milestone in the company’s expansion efforts. This strategic move positions Defence Therapeutics to leverage the resources and expertise available in one of the leading biotech clusters in the United States. By establishing a presence in this […]
Key Biotech News: Lyra’s Success, Sanofi’s Acquisition
In the latest biotech updates, Lyra Therapeutics celebrates a significant achievement while Sanofi makes a notable acquisition. These developments highlight the dynamic nature of the biotech industry in Boston, a hub for groundbreaking research and innovation. With biotech jobs on the rise in Massachusetts, the challenges of hiring skilled professionals remain a key focus for […]
iTeos Biotech Closure Impacts Cancer Therapeutics Sector
iTeos, a Watertown-based biotech company, announced its shutdown, mirroring a trend in the industry. This decision coincided with Keros Therapeutics’ discontinuation of a high blood pressure drug candidate, resulting in substantial layoffs. With Keros reducing its workforce by 45%, the aftermath leaves the company with only 85 employees, highlighting the challenges faced by biotech firms […]
AI-based urine test for prostate cancer shows success in clinical trial
PanGIA Biotech’s groundbreaking AI-based urine test for prostate cancer has achieved significant success in a recent clinical trial, marking a major milestone in the field of biotechnology. The test, designed to provide accurate and early detection of prostate cancer, has demonstrated promising results, offering potential benefits for patients and healthcare providers alike. This innovative technology […]
iTeos Ceases Operations in Watertown Biotech Sector
In a significant development for the biotech industry, iTeos has announced the closure of its operations in Watertown. This news comes amidst a series of setbacks for biotech companies, with Keros Therapeutics also recently ending the development of a drug candidate. The decision by iTeos is expected to have implications for the local biotech community […]
Moderna Secures FDA Approval for Next-Generation COVID-19 Vaccine
In a groundbreaking development, Moderna has received FDA approval for its cutting-edge COVID-19 vaccine, paving the way for its release in the upcoming 2025–2026 respiratory virus season. This milestone comes in the wake of the FDA’s introduction of a new approval framework for COVID-19 vaccines, signaling a new era in vaccine regulation. The announcement also […]
Pioneering Animal-to-Human Organ Transplant by eGenesis
In a groundbreaking development, biotech company eGenesis has successfully implanted a pig kidney into a second human patient, marking a significant advancement in animal-to-human organ transplants. This innovative procedure holds promise for addressing the critical shortage of human organs for transplantation, potentially revolutionizing the field of biotechnology and medical science. With eGenesis at the forefront […]
Impact of COVID-19 on Biotechs in Vaccine Development
The current uncertain landscape surrounding COVID-19 vaccines has led to major challenges for biotech companies. With reductions in funding for research and potential disruptions in the industry, experts like Cheng Li from Oppenheimer warn of long-term consequences on the development of breakthrough therapies. The shift of investments away from basic research towards more profitable areas […]
Enhanced Dual-Target CAR-T Cell Therapy Shows Promise in Glioblastoma Trial
A groundbreaking Phase I trial has revealed promising results for a novel Dual-Target CAR-T cell therapy in slowing the progression of aggressive glioblastoma tumors. This innovative approach targets multiple antigens on cancer cells, enhancing the effectiveness of the treatment. The findings offer hope for improved outcomes in patients with this challenging brain cancer. Stay informed […]
